India pharma market seen growing about 10% in FY27 as costs pressure margins
India Ratings expects domestic pharma demand to remain resilient, aided by chronic therapies, launches and GLP-1 adoption. However, rising material, freight and logistics costs, weaker US generics and regulatory scrutiny could soften sector margins.
What happened
India Ratings (Ind-Ra) · Ind-Ra expects India’s domestic pharma market to grow about 10% in FY27, supported by chronic therapies, new launches and GLP-1
Key facts
- Q1 FY27 revenue growth for 15 tracked pharma companies: high teens
- Industry sales growth in Q1 FY27: 11.5% year-on-year
- Expected domestic pharma market growth in FY27: around 10%
- July sales growth: 12.1%
- US revenues for 13 tracked companies: down 8% year-on-year in Q1 FY27
- US contribution to sector revenue: more than 35%
- Q1 FY27 gross margin: around 70%
- Q1 FY27 EBITDA margin: around 23%
Why this matters
Focus deal and partnership screening on differentiated chronic-care, GLP-1 and domestic-launch assets, with valuation discipline around cost pressures and exposure to US generics.
What to watch
- Monthly domestic pharma sales growth, especially chronic, anti-diabetic, cardiac and metabolic therapy segments.
- GLP-1 product launches, affordability initiatives, prescription growth and supply availability in India.
- API, intermediates, packaging, fuel, freight and logistics-cost trends.
- Domestic price-control actions, NPPA decisions and companies' ability to implement price increases outside controlled categories.
- US generic price erosion, ANDA approval cadence, channel inventory trends and FDA inspection outcomes.
- Quarterly gross-margin and EBITDA-margin guidance from large India-focused and US-exposed pharma companies.
- Shift salesforce, launch budgets and distribution capacity toward chronic, metabolic, diabetes and GLP-1-adjacent therapies.
- Pursue selective price increases, pack-size changes and trade-spend optimization in domestic branded portfolios.
- Lock in key API, packaging and freight contracts while increasing dual sourcing and domestic supplier qualification.
- Prioritize higher-margin domestic brands and complex/specialty export products over low-margin US commoditized generics.
- Increase regulatory-compliance investment and maintain inventory buffers for critical products to reduce disruption risk.
- Retail pharmacies and distributors are likely to expand shelf space, patient-support programs and cold-chain capabilities for chronic and GLP-1-linked demand.